Results for spaces (1 16), (1 25), (1 30), (1 3... translation from Danish to French

Danish

Translate

spaces (1 16), (1 25), (1 30), (1 32), (1 37)

Translate

French

Translate
Translate

Instantly translate texts, documents and voice with Lara

Translate now

Human contributions

From professional translators, enterprises, web pages and freely available translation repositories.

Add a translation

Danish

French

Info

Danish

(1, 75; 2, 16) (1, 32; 1, 71) (2, 35; 2, 88) 14- oh ↓0, 30 ↓0, 28 ↓0, 38

French

(1.75, 2.16) (1.32, 1.71) (2.35, 2.88) 14-oh ↓ 0.30 ↓ 0.28 ↓ 0.38 clarithromycine (0.26, 0.34) (0.24, 0.33) (0.34, 0.42) ↑ 1.28 ↔ 1.06 ↑ 1.91

Last Update: 2011-10-23
Usage Frequency: 1
Quality:

Warning: This alignment may be wrong.
Please delete it you feel so.

Danish

nevirapin auc ↑ 1, 25 (1, 17- 1, 34) nevirapin cmin ↑ 1, 32 (1, 22– 1, 43) nevirapin cmax ↑ 1, 17 (1, 09- 1, 25)

French

névirapine asc ↑ 1,25 (1,17-1,34) névirapine cmin ↑ 1,32 (1,22-1,43) névirapine cmax ↑ 1,17 (1,09-1,25)

Last Update: 2011-10-23
Usage Frequency: 1
Quality:

Warning: This alignment may be wrong.
Please delete it you feel so.

Danish

1 - 30 1 - 32 budgetbemyndigelse.

French

conseil européen.

Last Update: 2014-02-06
Usage Frequency: 2
Quality:

Danish

400 mg imatinib to gange daglig havde en inhibitorisk effekt på cyp2d6- medieret metoprololmetabolisme, som gav en stigning af cmax og auc for metoprolol på cirka 23% (90% ci [1, 16- 1, 30]).

French

l’ imatinib à 400 mg deux fois par jour avait un effet inhibiteur sur le métabolisme de métoprolol via le cyp2d6, avec une augmentation approximativement de 23% du cmax et de l’ asc du métoprolol (ic 90 %[1,16-1,30].

Last Update: 2011-10-23
Usage Frequency: 1
Quality:

Warning: This alignment may be wrong.
Please delete it you feel so.

Some human translations with low relevance have been hidden.
Show low-relevance results.

Get a better translation with
8,891,535,162 human contributions

Users are now asking for help:



We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. Learn more. OK